Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) EVP Anni Lotte Kirstine Pedersen sold 20,000 shares of Ascendis Pharma A/S stock in a transaction that occurred on Tuesday, November 17th. The shares were sold at an average price of $263.89, for a total value of $5,277,800.00. Following the sale, the executive vice president directly owned 19,460 shares in the company, valued at approximately $5,135,299.40. The trade was a 50.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Ascendis Pharma A/S Stock Down 0.3%
ASND stock opened at $270.33 on Thursday. Ascendis Pharma A/S has a fifty-two week low of $188.08 and a fifty-two week high of $282.15. The business’s 50 day moving average price is $242.90 and its two-hundred day moving average price is $240.53. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.29 and a current ratio of 2.89. The company has a market capitalization of $16.86 billion, a price-to-earnings ratio of 17.67 and a beta of 0.40.
Analyst Upgrades and Downgrades
Several brokerages have commented on ASND. Wedbush reissued an “outperform” rating and set a $327.00 price objective on shares of Ascendis Pharma A/S in a research report on Tuesday, September 1st. Wall Street Zen raised shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research report on Sunday, November 8th. KeyCorp set a $330.00 target price on shares of Ascendis Pharma A/S in a research report on Friday, November 13th. Raymond James Financial reiterated an “outperform” rating on shares of Ascendis Pharma A/S in a research note on Friday, November 13th. Finally, Bank of America lowered their price target on shares of Ascendis Pharma A/S from $306.00 to $304.00 and set a “buy” rating for the company in a research report on Monday, August 31st. Nineteen research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $312.67.
Get Our Latest Report on Ascendis Pharma A/S
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in ASND. Avior Wealth Management LLC purchased a new stake in shares of Ascendis Pharma A/S in the third quarter worth $1,193,000. Kornitzer Capital Management Inc. KS bought a new position in shares of Ascendis Pharma A/S during the third quarter valued at $3,778,000. Frazier Life Sciences Management L.P. increased its holdings in shares of Ascendis Pharma A/S by 68.9% during the second quarter. Frazier Life Sciences Management L.P. now owns 225,155 shares of the biotechnology company’s stock valued at $60,053,000 after acquiring an additional 91,822 shares in the last quarter. Orbimed Advisors LLC raised its position in shares of Ascendis Pharma A/S by 5.8% in the 1st quarter. Orbimed Advisors LLC now owns 181,977 shares of the biotechnology company’s stock worth $41,624,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its position in shares of Ascendis Pharma A/S by 1,105.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 17,305 shares of the biotechnology company’s stock worth $3,943,000 after purchasing an additional 15,870 shares during the last quarter.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.
Featured Stories
- Five stocks we like better than Ascendis Pharma A/S
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
